June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Endophthalmitis associated with XEN stent implantation
Author Affiliations & Notes
  • Benjamin Lin
    University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Hasenin Al-Khersan
    University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Elena Bitrian
    University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Harry W Flynn, Jr
    University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Benjamin Lin None; Hasenin Al-Khersan None; Elena Bitrian None; Harry Flynn, Jr None
  • Footnotes
    Support  NIH Center Core Grant P30EY014801
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4261. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Benjamin Lin, Hasenin Al-Khersan, Elena Bitrian, Harry W Flynn, Jr; Endophthalmitis associated with XEN stent implantation. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4261.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of this study is to report the clinical characteristics, causative organisms, and treatment outcomes in patients presenting with endophthalmitis related to XEN stent implants.

Methods : Clinical and microbiological review was performed for eight patients presenting to the Bascom Palmer Eye Institute Emergency Room from 2021 to 2022 with XEN stent related endophthalmitis. Data collected includes clinical characteristics of patients at presentation, organisms identified in ocular cultures, treatments received, and visual acuity at last follow up.

Results : The current study included eight eyes from eight patients. All cases of endophthalmitis occurred greater than 30 days after implantation of the XEN stent. At time of presentation, there was external exposure of the XEN stent in four out of the eight patients. Five of the eight patients had positive intraocular cultures, all of which were variants of staphylococcus and streptococcus species. Management included intravitreal antibiotics in all patients, explantation of the XEN stent in five patients (62.5%), and pars plana vitrectomy in six patients (75%). At last follow-up, six of the eight patients (75%) had a visual acuity of hand motion or worse.

Conclusions : Endophthalmitis in the setting of XEN stents results in poor visual outcomes. The most common causative organisms are staphylococcus or streptococcus species. At time of diagnosis, prompt treatment with broad spectrum intravitreal antibiotics is recommended. Consideration can be made to explant the XEN stent and perform early pars plana vitrectomy. Visual acuity outcomes are generally poor in these patients.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×